Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02162511 · ClinicalTrials.gov registry record · NA
CD34+ Cell Enriched and T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Mismatched Related Donors or Borderline Organ Function
A NA study of Non Malignant Diseases and Malignant Diseases, sponsored by Rajni Agarwal.
- Completed
- Registry status
- NA
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT02162511: Completed NA study of Non Malignant Diseases and Malignant Diseases, sponsored by Rajni Agarwal.
NCT02162511 is a NA study of Non Malignant Diseases and Malignant Diseases that has completed, run by Rajni Agarwal. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02162511, a NA study of Non Malignant Diseases and Malignant Diseases, has completed, sponsored by Rajni Agarwal.
- COMPLETED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this protocol is to provide access to the CliniMACS® System to hematopoietic cell transplant (HSCT) patients who do not have a matched related donor. The CliniMACS system is currently approved for use in patients who have AML, and a genetically matched sibling donor. Through this protocol, the investigators will be able to offer potentially life-saving transplants to patients who have genetically mis-matched donor, who have no other options for treatment.
Primary Outcome
GVHD is a condition that occurs when donor bone marrow or stem cells attack the recipient.
Conditions Studied
Interventions
- DEVICE CliniMACS CD34+ cell enrichment and T-cell depletion
Study Locations (1)
California
- Stanford Children's Hospital - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-05 |
| Est. Completion | 2023-03 |
| Phase | NA |
What the finished NCT02162511 record still lists
NCT02162511 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Non Malignant Diseases appearing as the primary indexed condition, and to 1 intervention - of which CliniMACS CD34+ cell enrichment and T-cell depletion is the first listed.
NCT02162511 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02162511 about?
NCT02162511 is a clinical study titled "CD34+ Cell Enriched and T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Mismatched Related Donors or Borderline Organ Function". The purpose of this protocol is to provide access to the CliniMACS® System to hematopoietic cell transplant (HSCT) patients who do not have a matched related donor. The CliniMACS system is currently approved for use in patients who have AML, and a genetically matched sibling donor. Through this prot...
What is the current status of trial NCT02162511?
This trial is currently completed. It is a NA study. The enrollment target is 3 participants. The study started on 2014-05. Estimated completion is 2023-03.
What conditions does trial NCT02162511 study?
This clinical trial studies the following conditions: Non Malignant Diseases, Malignant Diseases.
What interventions are being tested in trial NCT02162511?
The interventions under investigation include: CliniMACS CD34+ cell enrichment and T-cell depletion (DEVICE).
Who is sponsoring clinical trial NCT02162511?
This trial is sponsored by Rajni Agarwal, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02162511 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non Malignant Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02162511's enrollment target sits among peer trials
3 1996th of 2000 higher than 4 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia